The innate immune response in ischemic acute kidney injury

Jang, Hye Ryoun; Rabb, Hamid

doi:10.1016/j.clim.2008.08.016

Cited by 308 publications

(239 citation statements)

References 97 publications

Supporting

Mentioning

221

Contrasting

Unclassified

Order By: Relevance

“…Inhibiting the infiltration of T cells and macrophages has been shown to ameliorate the decline in renal function after ischemia-reperfusion, 54 but our study implies that a reduction in the inflammatory response is not a prerequisite for protecting renal function.…”

Section: Discussioncontrasting

confidence: 58%

Hypoxia-Inducible Transcription Factors Stabilization in the Thick Ascending Limb Protects against Ischemic Acute Kidney Injury

Schley

Klanke²,

Schödel³

et al. 2011

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Hypoxia-inducible transcription factors (HIF) protect cells against oxygen deprivation, and HIF stabilization before ischemia mitigates tissue injury. Because ischemic acute kidney injury (AKI) often involves the thick ascending limb (TAL), modulation of HIF in this segment may be protective. Here, we generated mice with targeted TAL deletion of the von Hippel-Lindau protein (Vhl), which mediates HIF degradation under normoxia, using Tamm-Horsfall protein (Thp)-driven Cre expression. These mice showed strong expression of HIF-1␣ in TALs but no changes in kidney morphology or function under control conditions. Deficiency of Vhl in the TAL markedly attenuated proximal tubular injury and preserved TAL function following ischemia-reperfusion, which may be partially a result of enhanced expression of glycolytic enzymes and lactate metabolism. These results highlight the importance of the thick ascending limb in the pathogenesis of AKI and suggest that pharmacologically targeting the HIF system may have potential to prevent and mitigate AKI.

show abstract

Section: Discussioncontrasting

confidence: 58%

Hypoxia-Inducible Transcription Factors Stabilization in the Thick Ascending Limb Protects against Ischemic Acute Kidney Injury

Schley

Klanke²,

Schödel³

et al. 2011

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…[47] After neovascularization, the ischemic tissue activates the immune system that may lead to further tissue injury. [47][48][49] For this reason it is essential that during optimization of cryopreservation/thawing protocols not only the viability of the follicles should be taken into account, but also the viability of the stromal cell compartment.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of ovarian tissue cryopreservation in a major European center

Bastings

Liebenthron

Westphal

et al. 2014

J Assist Reprod Genet

View full text Add to dashboard Cite

“…100 AKI has been shown to involve the contribution of multiple strategic players of innate immunity. 101 Following acute damage, inflammation mediates additional renal injury and dendritic cells seem to be crucial in summoning action from other immune cells. 102 Following injury, cytokines, growth factors and peptide molecules control M1 and M2 macrophages throughout the resolution phase, resulting in either regeneration of renal tissue or eventual evolution to fibrosis.…”

Section: Pathogenesismentioning

confidence: 99%

Acute kidney injury in HCT: an update

Lopes

Jorge

Neves

2016

Bone Marrow Transplant

View full text Add to dashboard Cite

Acute kidney injury (AKI) is highly prevalent whether the patients undergo myeloablative or non-myeloablative hematopoietic cell transplantation (HCT); however, the pathogenesis and risk factors leading to AKI can differ between the two. The prognosis of AKI in patients receiving HCT is poor. In fact, AKI following HCT is associated not only with increased short-and long-term mortality, but also with progression to chronic kidney disease. Herein, the authors provide a comprehensive and up-to-date review of the definition and diagnosis, as well as of the incidence, pathogenesis and outcome of AKI in patients undergoing HCT, centering on the differences between myeloablative and non-myeloablative regimens. INTRODUCTIONHematopoietic cell transplantation (HCT) is currently used to treat numerous malignant (for example, multiple myeloma, leukemias and lymphomas) and non-malignant hematological disorders (for example, aplastic anemia, b-thalassemia, immunodeficiency disorders and inborn errors of metabolism), as well as solid tumors (for example, breast cancer and neuroblastoma), which are in other instances incurable.The two major HCT procedures, taking into consideration the conditioning regimen used, are myeloablative autologous and allogeneic HCT and non-myeloablative allogeneic HCT. On the one hand, myeloablative HCT utilizes the maximally tolerated dose of TBI with or without chemotherapy, or with chemotherapy alone. On the other hand, non-myeloablative HCT depends more on donor cellular immune effects and less on the cytotoxic effects of the preparative regimen to control the underlying disease. 1,2 It ultimately uses a lower dose conditioning regimen and can thus be offered to older patients, to those debilitated by additional comorbidities, or to high-risk, heavily pretreated patients, who would not tolerate myeloablative HCT, resulting in a consequent decrease in regimen-related toxicity and treatment-related mortality. [3][4][5] Acute kidney injury (AKI) is highly prevalent whether the patients undergo myeloablative or non-myeloablative regimens; however, the pathogenesis and risk factors leading to AKI can differ between the two. In fact, AKI in patients receiving HCT is associated not only with increased short-and long-term mortality as compared with patients with no AKI, but also with a higher rate of progression to chronic kidney disease (CKD). Herein, the authors provide a comprehensive and up-to-date review of the definition and diagnosis of AKI as well as of the incidence, risk factors, pathogenesis and outcome of AKI in patients undergoing HCT, centering on the differences between myeloablative and nonmyeloablative regimens.

show abstract

The innate immune response in ischemic acute kidney injury

Cited by 308 publications

References 97 publications

Hypoxia-Inducible Transcription Factors Stabilization in the Thick Ascending Limb Protects against Ischemic Acute Kidney Injury

Hypoxia-Inducible Transcription Factors Stabilization in the Thick Ascending Limb Protects against Ischemic Acute Kidney Injury

Efficacy of ovarian tissue cryopreservation in a major European center

Acute kidney injury in HCT: an update

Contact Info

Product

Resources

About